T cell acute lymphoblastic leukaemia (T-ALL) is an aggressive haematological malignancy
derived from early T cell progenitors. In recent years genomic and transcriptomic studies …

T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive malignancy caused by the
accumulation of genomic lesions that affect the development of T cells. For many years, it …

The number of cancer survivors continues to increase because of both advances in early
detection and treatment and the aging and growth of the population. For the public health …

Cytotoxic chemotherapeutics primarily function through DNA damage-induced tumor cell
apoptosis, although the inflammation provoked by these agents can stimulate anti-cancer …

Purpose Blinatumomab is a bispecific T-cell engager antibody construct targeting CD19 on
B-cell lymphoblasts. We evaluated the safety, pharmacokinetics, recommended dosage, and …

Acute lymphoblastic leukaemia occurs in both children and adults but its incidence peaks
between 2 and 5 years of age. Causation is multifactorial and exogenous or endogenous …

Early T-cell precursor acute lymphoblastic leukaemia (ETP ALL) is an aggressive
malignancy of unknown genetic basis. We performed whole-genome sequencing of 12 ETP …

The cytokine TSLP has been shown to be a key factor in maintaining immune homeostasis
and regulating inflammatory responses at mucosal barriers. While the role of TSLP in type 2 …

Genomic profiling has identified a subtype of high-risk B-progenitor acute lymphoblastic
leukemia (B-ALL) with alteration of IKZF1, a gene expression profile similar to BCR-ABL1 …

Recently the World Health Organization (WHO), in collaboration with the European
Association for Haematopathology and the Society for Hematopathology, published a …